Skip to main content

Dr. James A. Scott, MD PHD.

Neurology (Diagnostic Neuroimaging (Psychiatry & Neurology) Physician)

  • Medicare participating

At a glance

Years since graduation
40
In the NPI registry since
2006
Medicare patients seen, 2024
1,090

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 1986Medical school: University of Florida College of Medicine
  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Diagnostic Neuroimaging (Psychiatry & Neurology) Physician primary
    FL license ME058332
  • Specialist
    FL license ME0058332

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Neurology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
1,090
Services billed
3,434
Patients’ average age
75
Most frequent Medicare services, 2023
ServiceTimesPatients
Established patient office or other outpatient visit, 30-39 minutes1,463681
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes768236
Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes255236
Measurement of brain wave activity (eeg), awake and asleep239216
Needle measurement of electrical activity in arm or leg muscles, complete study197109
New patient office or other outpatient visit, 60-74 minutes158158
Telehealth consultation, emergency department or initial inpatient, typically 70 minutes or more communicating with the patient via telehealth113108
Nerve conduction, 7-8 studies4947
Nerve conduction, 3-4 studies3636
Nerve conduction, 5-6 studies3030

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 32 companies reported 170 payments worth $4,346 in total to this clinician.

By type
Food and Beverage$4,001
Travel and Lodging$280
Education$64.43

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Feb 19, 2025Novartis Pharmaceuticals Corporation
Feb 19, 2025
Travel and Lodging
travel to Orlando, FL · in-kind
$280
Apr 8, 2025Amgen Inc.
Apr 8, 2025
Education
UPLIZNA · Inflammation/Rare Disease · in-kind
$28.63
Oct 8, 2025Janssen Pharmaceuticals, Inc
Oct 8, 2025
Education
in-kind
$17.90
Jul 11, 2025Janssen Pharmaceuticals, Inc
Jul 11, 2025
Education
in-kind
$17.90

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Florida →

Industry-funded research

Named as a principal investigator on 6 industry-funded studies in 2025, from 2 companies. The companies reported $849,806 in research payments for these studies, mostly to the institutions running them.

  • A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After …
    Novartis Pharmaceuticals Corporation
  • A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment …
    Novartis Pharmaceuticals Corporation
  • An Open label Single Arm Multi center Extension Study Evaluating Long term Safety Tolerability and Effectiveness of Ofatumumab in Subjects With Relapsing Multiple Sclerosis
    Novartis Pharmaceuticals Corporation
  • CCYB704A12301
    Hexal AG
  • A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis
    Novartis Pharmaceuticals Corporation
  • A multi-center, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate efficacy, safety, and tolerability of DII235 in adults with elevated lipoprotein(a)
    Novartis Pharmaceuticals Corporation

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Neurology clinicians in Ormond Beach

Sources

NPI registry (CMS NPPES, November 2026; record last updated September 27, 2017), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1952321671. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.